Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

662
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
662
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

616
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
616
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

782
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
782

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Benzo[a]pyrene on Targeted Therapy Response and Platelet-Activating Factor-Receptor-Mediated Microvesicle Particle Release in Non-Small Cell Lung Cancer.

Medical sciences (Basel, Switzerland)·2026
Same author

Commentary: Building Upon the History of Platelet-activating Factor Research to Garner Further Insights Involves Endogenous Acyl Platelet-activating Factor Inhibitors and Extracellular Vesicle Carriers.

Journal of atherosclerosis prevention and treatment·2026
Same author

Functional significance of miR-218 in lung cancer.

Journal of cancer metastasis and treatment·2026
Same author

Comparing Clinical vs Histopathological Features in Diagnosing Erythemato-Squamous Diseases.

Journal of clinical and investigative dermatology·2026
Same author

Evidence for microvesicle particles and platelet-activating factor as effectors for systemic effects of thermal burn injury.

Frontiers in immunology·2026
Same author

Repurposing Itraconazole in Combination with Chemotherapy and Immune Checkpoint Inhibitor for Cancer.

Medical sciences (Basel, Switzerland)·2026

Related Experiment Video

Updated: Apr 13, 2026

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.5K

Systemic chemotherapy is modulated by platelet-activating factor-receptor agonists.

Ravi P Sahu1, Matheus Ferracini2, Jeffrey B Travers3

  • 1Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA ; Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

Mediators of Inflammation
|April 30, 2015
PubMed
Summary

Platelet-activating factor-receptor (PAF-R) agonists generated during chemotherapy can suppress anti-tumor immunity. This study shows these agonists also reduce the effectiveness of systemic chemotherapy against melanoma.

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

2.2K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.3K

Related Experiment Videos

Last Updated: Apr 13, 2026

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.5K
Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

2.2K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.3K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Chemotherapy is a cornerstone in cancer treatment, yet its efficacy is often limited by immunosuppression.
  • Oxidized lipids with platelet-activating factor-receptor (PAF-R) agonistic activity have been shown to induce systemic immunosuppression, promoting experimental melanoma growth.
  • Previous research indicated that chemotherapy can generate these PAF-R agonists, which may augment tumor growth.

Purpose of the Study:

  • To investigate the impact of PAF-R agonists on the efficacy of systemic chemotherapy against experimental melanoma.
  • To determine if PAF-R agonists interfere with the anti-tumor effects of systemic chemotherapy.

Main Methods:

  • Systemic chemotherapy using etoposide (ETOP) was administered to mice with melanoma tumors.
  • The effect of ETOP on tumor growth was assessed.
  • The impact of exogenous PAF-R agonist (CPAF) administration on ETOP's efficacy was evaluated.

Main Results:

  • Systemic chemotherapy with etoposide (ETOP) significantly attenuated the growth of melanoma tumors.
  • The anti-tumor effect of ETOP was significantly blocked by the exogenous administration of a PAF-R agonist (CPAF).
  • These findings suggest PAF-R agonists compromise the efficacy of systemic chemotherapy against melanoma.

Conclusions:

  • PAF-R agonists play a detrimental role in chemotherapy's anti-tumor activity.
  • The generation or administration of PAF-R agonists can reduce the effectiveness of systemic chemotherapy for melanoma.
  • Targeting PAF-R signaling may represent a novel strategy to enhance chemotherapy outcomes in melanoma treatment.